Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype.

MLA

Pallet, N., et al. “Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype.” American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, vol. 16, no. 9, Sept. 2016, pp. 2670–75. EBSCOhost, https://doi.org/10.1111/ajt.13788.

APA

Pallet, N., Etienne, I., Buchler, M., Bailly, E., Hurault de Ligny, B., Choukroun, G., Colosio, C., Thierry, A., Vigneau, C., Moulin, B., Le Meur, Y., Heng, A.-E., Legendre, C., Beaune, P., Loriot, M. A., & Thervet, E. (2016). Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons, 16(9), 2670–2675. https://doi.org/10.1111/ajt.13788

Chicago

Pallet, N, I Etienne, M Buchler, E Bailly, B Hurault de Ligny, G Choukroun, C Colosio, et al. 2016. “Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype.” American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons 16 (9): 2670–75. doi:10.1111/ajt.13788.